OptiBiotix Health Plc, a life sciences company, (OPTBF) Fair Value & Analysis
Healthcare · US · Market cap $11.4M
Fair value as of: Jun 26, 2026
Analysis
OptiBiotix Health Plc, a life sciences company, (OPTBF) currently trades at $0.1100, while our model-based Fair Value estimate is $0.2100 — implying the stock looks roughly 90.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; and WellBiome a novel in vitro model of the human gut. In addition, the company offers second-generation solutions, including Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners; and Microbiome Modulators. Further, it provides CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; OptiBiotics, a portfolio of prebiotics developed to target…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is OptiBiotix Health Plc, a life sciences company, (OPTBF) undervalued?
What is the fair value of OPTBF?
What is the quality score of OPTBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.